Stockreport

Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones [Yahoo! Finance]

Contineum Therapeutics, Inc. - Common stock  (CTNM) 
PDF Topline data from PIPE-307 Phase 2 VISTA trial for the treatment of relapsing-remitting multiple sclerosis (RRMS) anticipated in the second half of 2025 Cash runway p [Read more]